Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. II. Studies implicating transporter-mediated intestinal secretion

Reference

• BARDELMEIJER, H. A., BEIJNEN, J. H., BROUWER, K. R., ROSING, H., NOOIJEN, W. J., SCHELLENS, J. H. M. and VAN TELLINGEN, 0., 2000, Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clinical Cancer Research, 6, 4416–4421.
   Google Scholar
• BENET, L. Z. and CUMMINS, C. L., 2001, The drug efflux-metabolism alliance: Biochemical aspects. Advanced Drug Delivery Reviews, 50, S3–S11.
   Google Scholar
• BENET, L. Z., Izumi, T., ZHANG, Y., SILVERMAN, J. A. and WACHER, V. J., 1999, Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. Journal of Controlled Release, 62, 25–31.
   PubMed Web of Science ®Google Scholar
• BENET, L. Z., Wu, C.-Y., HEBERT, M. F. and WACHER, V. J., 1995, Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. Journal of Controlled Release, 39, 139–143.
   Google Scholar
• DAVIES, B. and MORRIS, T., 1993, Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093–1095.
   PubMed Web of Science ®Google Scholar
• EVERS, R., KOOL, M., SMITH, A. J., VAN DEEMTER, L., DE HAAS, M. and BORST, P., 2000, Inhibitory effect of the reversal agents V-104, GF120918 and pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. British Journal of Cancer, 83, 366–374.
   PubMed Web of Science ®Google Scholar
• FRICKER, G. and MILLER, D. S., 2002, Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. Pharmacology and Toxicology, 90, 5–13.
   PubMedGoogle Scholar
• HYAFIL, F., VERGELY, C., Du VIGNAUD, P. and GRAND-PERRET, T., 1993, In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Research, 53, 4595–4602.
   Google Scholar
• INSTITUTE OF LABORATORY ANIMAL RESOURCES, 1996, Guide for the Care and Use of Laboratory Animals (Washington: National Academy Press).
   Google Scholar
• JONKER, J. W., SMIT, J. W., BRINKHUIS, R. F., MALIEPAARD, M., BEIJNEN, J. H., SCHELLENS, J. H. M. and SCHINKEL, A. H., 2000, Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Journal of the National Cancer Institute, 92, 1651–1656.
   Google Scholar
• KUSUHARA, H., SUZUKI, H. and SUGIYAMA, Y., 1998, The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. Journal of Pharmaceutical Sciences, 87, 1025–1040.
   PubMed Web of Science ®Google Scholar
• LETRENT, S. P., POLLACK, G. M., BROUWER, K. R. and BROUWER, K. L. R., 1999, Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metabolism and Disposition, 27, 827–834.
   PubMed Web of Science ®Google Scholar
• MATHENY, C. J., LAMB, M. W., BROUWER, K. L. R. and POLLACK, G. M., 2001, Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy, 21, 778–796.
   Google Scholar
• MILLER, W. H., KEENAN, R. M., WILLETTE, R. N. and LARK, M. W., 2000, Identification and in vivo efficacy of small-molecule antagonists of integrin 007133 (the vitronectin receptor). Drug Discovery Today, 5, 397–408.
   PubMed Web of Science ®Google Scholar
• PRUEKSARITANONT, T., MENG, Y., MA, B., LEPPERT, P., HOCHMAN, J., TANG, C., PERKINS, J., ZRADA, M., MEISSNER, R., DUGGAN, M. E. and LIN, J. H., 2002, Differences in the absorption, metabolism and biliary excretion of a diastereometric pair of cv33-antagonists in rat: Limited role of P-glycoprotein. Xenobiotica, 32, 207–220.
   PubMed Web of Science ®Google Scholar
• ROWLAND, M. and TOZER, T. N., 1995, Clinical Pharmacokinetics: Concepts and Applications (Philadelphia: Lippincott Williams & Wilkins).
   Google Scholar
• SANDSTRöM, R., KARLSSON, A. and LENNERNAS, H., 1998, The absence of stereoselective P-glycoprotein-mediated transport of R/S-verapamil across the rat jejunum. Journal of Pharmacy and Pharmacology, 50, 729–735.
   PubMed Web of Science ®Google Scholar
• SPARREBOOM, A., PLANTING, A. S. T., JEWELL, R. C., VAN DER BURG, M. E. L., VAN DER GAAST, A., DE BRUIJN, P., Loos, W. J., NOOTER, K., CHANDLER, L. H., PAUL, E. M., WISSEL, P. S. and VERWEIJ, J., 1999, Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycorprotein. Anti-Cancer Drugs, 10, 719–728.
   Google Scholar
• VAN ASPEREN, J., VAN TELLINGEN, 0. and BEIJNEN, J. H., 1998, The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacological Research, 37, 429–435.
   Google Scholar
• WACHER, V. J., SALPHATI, L. and BENET, L. Z., 2001, Active secretion and enterocytic drug metabolism barriers to drug absorption. Advanced Drug Delivery Reviews, 46, 89–102.
   PubMed Web of Science ®Google Scholar
• WALLSTAB, A., KOESTER, M., BöHME, M. and KEPPLER, D., 1999, Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. British Journal of Cancer, 79, 1053–1060.
   Google Scholar
• WARD, K. W., AZZARANO, L. M., BONDINELL, W. E., COUSINS, R. D., HUFFMAN, W. F., JAKAs, D. R., KEENAN, R. M., Ku, T. W., LUNDBERG, D., MILLER, W. H., MUMAW, J. A., NEWLANDER, K. A., PIRHALLA, J. L., ROETHKE, T. R., SALVERS, K. L., SOUDER, P. R., STELMAN, G. J. and SMITH, B. R., 1999, Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metabolism and Disposition, 27, 1232–1241.
   PubMed Web of Science ®Google Scholar
• WARD, K. W., AZZARANO, L. M., EVANS, C. A. and SMITH, B. R., 2004, Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations. Xenobiotica, 34, 353–366.
   PubMed Web of Science ®Google Scholar